Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resist...
Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands
CARD: Cabazitaxel vs abiraterone or enzalutamide in metastatic castration-resistant prostate cancer ( Prof Ronald de Wit - Erasmus University Medical Center, Rotterdam, Netherlands )
7 Oct 2019
IMspire170: New combination treatment for advanced melanoma
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
IMspire170: New combination treatment for advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanom...
Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain
CheckMate 067: Nivolumab plus ipilimumab combination therapy in advanced melanoma ( Dr Ana Arance - Hospital Clinic Barcelona, Barcelona, Spain )
7 Oct 2019
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma
Jonathan Ledermann - University College Hospital, London, UK
ARIEL3: Rucaparib maintenance treatment for recurrent ovarian carcinoma ( Jonathan Ledermann - University College Hospital, London, UK )
7 Oct 2019
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural m...
Prof Sanjay Popat - The Royal Marsden Hospital, London, UK
PROMISE-meso trial results: Pembrolizumab vs chemotherapy for advanced pleural mesothelioma ( Prof Sanjay Popat - The Royal Marsden Hospital, London, UK )
7 Oct 2019
PARP inhibitors for metastatic breast cancer
Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
PARP inhibitors for metastatic breast cancer ( Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
KATHERINE trial updates for HER2-positive breast cancer
Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany
KATHERINE trial updates for HER2-positive breast cancer ( Prof Michael Untch - Helios Hospital Berlin-Buch, Berlin, Germany )
7 Oct 2019
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer
Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Irela...
TRITON2: Rucaparib for metastatic castration-resistant prostate cancer ( Prof Ray McDermott - St. Vincents University Hospital, Dublin, Republic of Ireland )
7 Oct 2019
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast can...
Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA
MEDIOLA: Olaparib and durvalumab for germline BRCA-mutated metastatic breast cancer ( Prof Susan Domchek - University of Pennsylvania, Pennsylvania, USA )
4 Oct 2019
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk ...
Prof Pieter Sonneveld - Erasmus MC Cancer Institute, Rotterdam, Netherlands
D-VTd in transplant-eligible newly diagnosed MM: Subgroup analysis of high-risk patients in CASSIOPEIA ( Prof Pieter Sonneveld -  Erasmus MC Cancer Institute, Rotterdam, Netherlands )
25 Sep 2019
Real-world use of carfilzomib therapy among patients with existing cardiovascula...
Prof Xavier Leleu - CHU la Miletrie, Poitiers, France
Real-world use of carfilzomib therapy among patients with existing cardiovascular medical history ( Prof Xavier Leleu - CHU la Miletrie, Poitiers, France )
25 Sep 2019
BCMA: A new biomarker for multiple myeloma
Dr James Berenson - Oncotherapeutics, West Hollywood, USA
BCMA: A new biomarker for multiple myeloma ( Dr James Berenson - Oncotherapeutics, West Hollywood, USA )
25 Sep 2019